Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TAK 603

Known as: TAK-603 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
BACKGROUND The therapeutic efficacy of the regulation of T helper (Th)-1-predominant immune responses remains to be investigated… Expand
Is this relevant?
2004
2004
BACKGROUND AND AIM Sarcoidosis is immunologically characterized by highly enhanced Th1 responses in active stage. TAK-603 is a… Expand
Is this relevant?
2003
2003
  • Francine M Foss
  • Journal of cutaneous medicine and surgery
  • 2003
  • Corpus ID: 39824536
Graft-vs-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation. GVHD… Expand
Is this relevant?
2001
2001
Acute graft-versus-host diseases (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1999
1999
In the course of our studies aimed at obtaining new drugs for treatment of bone and joint diseases, chemical modification of the… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
1999
1999
A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these… Expand
Is this relevant?
1998
1998
The disposition of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-1-ylmethyl) quinoline-3-carboxylate (CAS 158146… Expand
Is this relevant?
1998
1998
The metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmeth yl)quinoline -3-carboxylate (1, TAK-603… Expand
Is this relevant?
1997
1997
We have shown that TAK-603, a new anti-rheumatic drug, is more effective in animal models in which cellular immunity plays a… Expand
Is this relevant?
1996
1996
We investigated the pharmacological activities of a newly synthesized anti-rheumatic drug, TAK-603. (1) In vivo: In adjuvant… Expand
Is this relevant?